Compare Travere Therapeutics Inc. Common Stock (TVTX) vs United Parcel Service Inc (UPS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Travere Therapeutics Inc. Common Stock vs United Parcel Service Inc — how do they compare? Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B), while United Parcel Service Inc trades at $95.91 (market cap $80.65B). The key difference: United Parcel Service Inc is far larger — about 16.5× Travere Therapeutics Inc. Common Stock's market cap, and United Parcel Service Inc pays a 6.92% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Travere Therapeutics Inc. Common Stock for 0 Days and United Parcel Service Inc for 141 Days on average.
| TVTX | UPS | |
|---|---|---|
Market Cap | $4.88B | $80.65B |
Volume | 1,668,577 | 3,099,263 |
Sector | Health | Industrials |
52-Week High | $67.52 | $120.00 |
52-Week Low | $26.79 | $84.09 |
Typical Hold Time | 0 Days | 141 Days |
Enterprise Value | $5.01B | $104.67B |
Dividend Yield | — | 6.92% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
UPS stock trades at $95.77, up 0.45% on the day, with a bullish technical signal despite mixed moving averages. The company shows consistent earnings beats, with Q3 2026 results pending, and maintains solid profitability with a 5.08% net margin and 29.66% ROE. Recent news highlights strategic moves like the TikTok Shop partnership and Secure Commerce platform launch to bolster e-commerce security and margins.
The outlook is cautiously optimistic, supported by analyst consensus of $118.67 price target and 46.7% buy ratings, but risks include declining revenue trends, competitive pressures from Amazon, and fuel cost volatility. The stock's 7% dividend yield offers income appeal, though margin sustainability remains a key watchpoint for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →About United Parcel Service Inc
United Parcel Service, Inc. (UPS) delivers packages and documents throughout the United States and in other countries and territories. The Company also provides global supply chain services and less-than-truckload transportation, primarily in the US UPS's business consists of integrated air and ground pick-up and delivery network
Read more on UPS →
